Financial reports
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
23 Mar 22
Current reports
8-K
Departure of Directors or Certain Officers
5 Apr 24
8-K
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides
11 Mar 24
8-K
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
7 Mar 24
8-K
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
27 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
7 Dec 23
8-K
Departure of Directors or Certain Officers
22 Nov 23
8-K
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
9 Nov 23
8-K
VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16
6 Nov 23
8-K
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis
10 Oct 23
8-K
Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress
10 Aug 23
Registration and prospectus
S-3
Shelf registration
9 Apr 24
POS AM
Prospectus update (post-effective amendment)
27 Feb 24
POSASR
Automatic shelf registration (post-effective amendment)
13 Feb 24
S-8
Registration of securities for employees
2 Jan 24
S-8
Registration of securities for employees
5 Jan 23
POS AM
Prospectus update (post-effective amendment)
20 Dec 22
S-3ASR
Automatic shelf registration
20 Dec 22
424B3
Prospectus supplement
4 Oct 22
S-1
IPO registration
26 Sep 22
S-8
Registration of securities for employees
21 Oct 21
Other
EFFECT
Notice of effectiveness
23 Dec 22
EFFECT
Notice of effectiveness
5 Oct 22
CORRESP
Correspondence with SEC
30 Sep 22
UPLOAD
Letter from SEC
30 Sep 22
EFFECT
Notice of effectiveness
21 Oct 21
CERT
Certification of approval for exchange listing
20 Oct 21
CORRESP
Correspondence with SEC
18 Oct 21
CORRESP
Correspondence with SEC
18 Oct 21
CORRESP
Correspondence with SEC
14 Oct 21
UPLOAD
Letter from SEC
12 Oct 21
Ownership
4
Somu Subramaniam
16 Apr 24
4
Change in insider ownership
16 Apr 24
SC 13G
Flynn James E
4 Apr 24
4
Christopher W Krueger
3 Apr 24
4
John Nuss
3 Apr 24
4
Raju Mohan
3 Apr 24
4
Martin Auster
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24